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Inflammatory bowel disease (IBD) is a chronic, relapsing and 
remitting inflammation of the intestine, posing significant treatment 
challenges. Maintenance treatment with an immunomodulator (IM) 
and/or aminosalicylates is often required to reduce disease relapse in 
Crohn’s disease (CD) and ulcerative colitis (UC). Despite adequate 
maintenance therapy, some patients experience disease flares that 
require escalation to biological therapy.[1,2] 
As there is currently no cure available for IBD, the treatment 
strategy for patients focuses on induction and maintenance of 
remission. As South Africa (SA) is a developing country and 
biological drug cost prohibitive, the (accelerated) step-up treatment 
strategy is used, with high-dose corticosteroids the favourite 
induction agent. This is followed by maintenance therapy with 
aminosalicylates or an IM to maintain remission. Examples of IM 
agents include azathioprine, 6-mercaptopurine and methotrexate. 
Thioguanine (Lanvis) is also used for severe IBD in an off-label 
setting in some centres. Patients who experience disease flares while 
receiving adequate doses of maintenance therapy and/or require a 
second course of high-dose corticosteroid therapy within a short 
treatment interval (usually 1 year), are escalated to biological therapy. 
Other indications for biological treatment include steroid-dependant 
and steroid-refractory disease.
Since the launch of infliximab 20 years ago, the number of 
biological agents introduced to the market has grown exponentially, 
especially in the past decade. Currently available classes of biological 
agents for IBD in SA include: (i) tumour necrosis factor alpha 
(TNF alpha) antagonists, which include infliximab, adalimumab 
and golimumab; (ii) the integrin antagonist vedolizumab (Entyvio); 
and (iii) ustekinumab, a newly introduced interleukin (IL)-12 
and IL-23 anta gonist (Stelara).[3-7] The last two agents are awaiting 
SA Health Products Regulatory Authority (SAHPRA) approval and 
currently only have limited availability on compassionate basis.
Biological agents have revolutionised the treatment of IBD, 
especially over the past decade. A recent systematic review by Cote-
Diagneault et al.[8] comprehensively summarised the success rate of 
IBD treatment with biologics. A detailed discussion of this topic is 
beyond the scope of this article, but salient points are summarised 
below. Although study designs and patient characteristics differ 
in various studies, it is apparent that induction and maintenance 
of remission rates are ˂50% for both CD and UC. Analysing the 
maintenance of remission data, it is clear that clinical response rates 
are better than clinical remission rates, which in turn are better than 
mucosal healing. Data from real-world registries have far superior 
clinical response and remission rates than clinical trial data. A 
recent systematic review concluded that biological therapy effectively 
reduced hospitalisation by half and surgery by 33 - 77%.[9] More 
importantly, it reduced steroid-free remission by 30%.[10] 
Secondary loss of response (LOR) while the patient is being treated 
with a biological agent is a significant problem in IBD management 
and often results in disease relapse. It is estimated that up to 30% 
of patients do not respond to induction therapy and a further 30% 
develop LOR.[11] LOR is believed to be secondary to the development 
of drug antibodies, with resultant low drug trough levels. This is often 
remedied by dose escalation of the biologic in question if the trough 
drug level is low or by switching to a different agent if the drug level 
is within target range. For example, if a patient is maintained on a 
standard dose of infliximab (5 mg/kg every 8 weeks), it will increase 
to a 10 mg/kg dose every 8 weeks with dose escalation. However, 
more often, the dosing frequency is also reduced in addition to dose 
escalation, resulting in a 10 mg/kg dose given every 6 weeks or even 
every 4 weeks. Similar treatment strategies exist for the other agents. 
Biological therapy
The clinical efficacy of biological therapy in moderate to severe CD 
and UC is well established in the scientific literature.[12] The decision 
to initiate biological therapy in this setting is often made easily, as 
treatment objectives and algorithms are clear.[13] The clinical benefits of 
biological therapy include: higher rates of mucosal healing, improved 
quality of life, reduced hospital admission rates and fewer surgical 
interventions. However, biological therapy is associated with significant 
adverse events and high treatment cost. The major negative factors are 
serious infections and possible increased risk of malignancy.[14] 
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Therefore, when deciding to start biological therapy in IBD, the risk 
of treatment should be carefully balanced against the benefit, i.e. the 
danger of uncontrolled or untreated IBD should always be greater than 
that of therapy. However, it is currently not clear when to de-escalate 
biological therapy. The rationale for de-escalation includes: 
• Cost of therapy. Treatment cost for indefinite treatment with 
biological agents is considerable.[15] The cost escalates notably if the 
patient requires a dose increase and/or reduced dosing frequency. 
The direct cost for the first year of biological therapy in SA for 
2018 is set out in Table 1. The total cost excludes hospitalisation, 
consumables for infusion and endoscopy costs, which further 
increases overall cost significantly.
• Safety concerns. Anti-TNF antagonists especially have a significant 
adverse profile, adding to the morbidity with regard to IBD 
treatment. However, newer and safer classes of biological agents 
are currently awaiting SAHPRA approval, which should improve 
the safety profile. Although not evidence based, the possibility 
remains that some toxicity of biological treatment may be directly 
related to the cumulative duration or dose of the drug, a concern 
not always considered in clinical practice. 
• Patient-specific reasons
• Adherence to drug therapy. This has often been a bone of 
contention between the patient and the treating physician. Up 
to 30% of IBD patients discontinue maintenance therapy,[16] 
although compliance with biological therapy was high – 94% in 
a recent Italian study.[17] 
• Safety concerns. Patients often want to de-escalate therapy, 
especially when they are clinically well. The same applies to 
pregnant and breastfeeding patients. Patients are not keen to 
take unnecessary risks and their decision to discontinue therapy 
is usually based on: (i) their chances of disease relapse; and (ii) when 
they do relapse, how long it will take to reach clinical remission 
with the same or a similar drug. 
In the next section, we try to answer some of these questions and 
implications.
Risk of relapse after withdrawal of 
biological agents
There is no randomised controlled study that has evaluated the effect 
of withdrawal of a biological agent as monotherapy in IBD. Available 
studies investigated infliximab and adalimumab in combination 
with IM therapy. No similar comparative studies are available for 
other biological agents. A recent meta-analysis considering relapse 
after withdrawal of anti-TNF therapy (infliximab and adalimumab) 
showed UC and CD relapse rates of 38% and 44% after 6 months and 
28% and 42% after 1 year, respectively.[18] Inversely, >60% of patients 
with CD and ≥70% of patients with UC remain in remission 1 year 
after withdrawal of anti-TNF therapy. In the STORI (infliximab 
diSconTinuation in crOh’ns disease patients in stable RemIssion) 
trial, discontinuing anti-TNF treatment in CD patients receiving 
combination therapy, the relapse rate was 43.9% after 12 months and 
52.2% after 24 months, with a median of 16.4 months to relapse.[19] 
In UC studies, where anti-TNF therapy was withdrawn and patients 
remained on an IM, stopping anti-TNF was associated with relapse 
rates of 14.0 - 41.8% after 12 months and 25.0 - 58.7% at 24 months.[20,21] 
Relapse rates were significantly reduced when mucosal healing was 
used as the reference point to de-escalate anti-TNF therapy (17 - 24% 
after 12 months and 25 - 35% after 24 months).[22] 
Limited data exist for longer follow-up after withdrawal of biological 
agents. There is a relapse risk of 50% after withdrawal at 24 months 
of anti-TNF therapy, according to 1 meta-analysis and 1 systematic 
review.[18,23] Reported long-term cumulative relapse rates are between 
49% and 88%. A period of 5 - 10 years off biological treatment is 
associated with relapse rates of >70%.[24-26] Therefore, the risk of 
disease relapse increases with time, necessitating the re-introduction 
of biological therapy. However, a minority of patients remain in 
remission indefinitely without requiring any active treatment.
Risk factors for relapse after treatment 
withdrawal
Various factors predicting relapse have been evaluated and are 
categorised as follows: 
• Patient factors. The outstanding risk factor for disease relapse 
after de-escalation of anti-TNF therapy is continued smoking in 
CD patients.[27] The reverse is true for smoking in UC, but should 
be discouraged in all patients, as the negative effects of smoking 
outweigh the potential benefit in UC. Young age at diagnosis 
appears to be associated with severe disease in both CD and UC, 
but data are conflicting.[28] Gender per se is not a risk factor for 
aggressive IBD; however, young males are at increased risk of 
severe CD.[29,30]
• Disease factors. Mucosal healing at the time of treatment withdrawal 
is associated with a reduced risk of disease relapse.[18] For CD, when 
biological therapy is discontinued based only on clinical remission, 
disease relapse rates are 42% at 1 year, but these are reduced to 26% 
when therapy is stopped with mucosal healing. Similarly, for UC, 
1-year relapse rates vary from 50% in cases of clinical remission 
to 33% in those of mucosal healing.[18,31] Fistulising peri-anal CD 
has consistently been associated with increased relapse rates after 
treatment withdrawal. A possible increased risk of relapse has been 
reported in complex CD with strictures and fistulas, but the data are 
inconclusive.[32,33] Previous surgery alone has not been associated 
with an increased relapse rate.[34] 
• Laboratory data. A high C-reactive protein (CRP) and faecal 
calprotectin (FC) at time of treatment withdrawal are associated 
with increased disease relapse.[35-37] An optimal predictive cut-off 
for relapse for CRP was 6.1 mg/L and 305 μg/g for FC, although 
sensitivity and specificity for both were low (~70%). A low 
haemoglobin and raised white cell count >6 × 109/L may increase 
risk of relapse.[34] High infliximab trough levels at time of anti-TNF 
withdrawal are also associated with an increased relapse rate.[34] 
Table 1. Induction and maintenance cost for the first year of biological therapy in South Africa 
Biological therapy Induction Cost, ZAR Maintenance Cost, ZAR Total cost/year, ZAR
Infliximab 400 mg* weeks 0, 2 and 6 67 520.52 400 mg* every 8 weeks 112 534.20 180 054.72
Adalimumab† 160 mg week 0; 80 mg week 2 34 571.60 40 mg every other week 113 592.40 148 164.00
Golimumab‡ 200 mg week 0; 100 mg week 2 31 338.69 100 mg every 4 weeks 114 908.53 146 247.22
*Infliximab: dose 5 mg/kg based on patient weight of 80 kg; 100 mg vial = ZAR5 626.71.
†Adalimumab: 40 mg vial = ZAR4 938.80.
‡Golimumab: 100 mg vial = ZAR10 446.23.
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• IM therapy. Previous treatment failure with an IM prior to starting 
anti-TNF therapy was associated with increased disease recurrence 
after discontinuing the biological agent.[38] Moreover, absence of 
IM therapy after stopping biological therapy was associated with a 
higher relapse rate in some studies.[18] 
• Elevated levels of the cytokines. Elevated levels of the cytokines 
IL-17 and TNF alpha in the healed mucosa of patients with IBD 
may also predict early disease relapse after stopping biological 
therapy.[39] Colonoscopy and a colonic mucosal biopsy are not 
standard practice in otherwise well patients, and the introduction 
of cytokine analysis in this setting may be inappropriate. A clinical 
study examining serum inflammatory cytokines to predict disease 
relapse may yield useful results that could be easier to implement.
Retreatment strategies after relapse
Retreatment with the same biological agent used prior to 
discontinuation is safe and effective. A recent meta-analysis showed 
retreatment with the same anti-TNF agent induced clinical remission 
in an average of 80% of IBD patients, with similar outcomes in CD 
and UC.[18] Much the same results were shown in the STORI trial.[19] 
Longer follow-up data in retreatment studies confirmed remission 
rates in these patients (80 - 92% at 1 year).[20,36] 
An important effect of retreatment is the high risk of immunisation 
resulting in hypersensitivity reactions and ultimately loss of drug 
response. This can be countered by concomitant IM therapy that 
reduces antibody formation, resulting in less infusion reactions and loss 
of response.[40] Furthermore, discontinuation of IM during combination 
therapy resulted in secondary LOR and anti-TNF dose escalation in 
24% of patients.[41] A recent study showed infusion reactions in 24% 
of patients who were retreated with infliximab after a drug holiday. 
Seventeen percent had to discontinue infliximab altogether owing 
to the severity of the infusion reactions. However, patients on an IM 
during the drug holiday had fewer infusion reactions.[42]
Discontinuing biological agents in 
special groups
There are certain patient groups that respond differently to conventional 
drug treatment and withdrawal of treatment. These are discussed below:
• Pregnancy. Anti-TNF antibodies cross the placenta and because 
of increased risk of infection to the newborn have traditionally 
been discontinued in the third trimester.[43] However, a recent 
Toronto consensus statement recommended that biological 
treatment should be continued during the entire pregnancy.[44] 
Discontinuation of treatment increases the risk of disease flare 
in the third trimester or in the postpartum period. In a 2011 
retrospective study by Seirafi et al.,[45] 14% relapsed in the third 
trimester and 32% in the first 3 weeks postpartum. A more recent 
study showed third-trimester relapse rates of 9.8% and 3 months 
postpartum relapse rates of 15.7%.[46] Retreatment with the same 
biological agent in the same study during the postpartum period 
resulted in 100% clinical remission rates. The decision to stop or 
continue treatment during pregnancy should be individualised and 
patients with aggressive disease should probably be persuaded to 
remain on a biological agent throughout. 
• Perianal CD. Data regarding treatment withdrawal in this group of 
patients are sparse. A 2005 study showed that only a third of patients 
with luminal perianal disease remained in clinical remission 1 year 
after stopping infliximab.[47] In the ACCENT-II trial (a CD clinical 
trial evaluating infliximab in a new long-term treatment regimen in 
patients with fistulising CD), only 36% of patients with fistulising 
perianal CD achieved a clinical response (inactive disease and 
closed fistulas) after 54 weeks of infliximab therapy.[48] Withdrawal 
of infliximab in patients with fistulising perianal disease after clinical 
remission (healed mucosa, closed fistulas) resulted in a relapse rate 
of 24% in 1 year and 55% in 5 years, as shown in a recent study by 
Legué et al.[49] Complex perianal CD also has a poor clinical response 
to long-term infliximab maintenance treatment, with a failure 
rate of 15.4% at 15 weeks and >40% at 5 years.[50] It appears that 
a combination of surgery and biological therapy remains the most 
effective treatment choice.[51]
• Postoperative prophylaxis. CD often recurs after surgical resection. 
Treatment with biological therapy was found to be the most effective 
way of reducing postoperative recurrence. Regueiro et al.[52] noted 
a 100% disease recurrence in 1 year after stopping biological 
therapy after surgery. A disease recurrence rate of 83% was noted 
by Sorrentino et al.[53] 4 months after discontinuing infliximab 
after surgical resection. However, recent data suggest that long-
term infliximab treatment after surgery prevents endoscopic – but 
not clinical – disease recurrence.[54] Retreatment with the same 
biological drug in relapsed patients who discontinued biological 
therapy in this setting resulted in clinical remission in all. 
• Pouchitis. This is often difficult to manage. Results with anti-TNF 
therapy for refractory pouchitis is reassuringly good. A recent 
systematic review showed that infliximab has 80% short-term and 
50% long-term clinical efficacy in refractory pouchitis.[55] However, 
there are no consistent long-term outcome data and it is unclear 
how long one should continue with therapy.[56]
De-escalation strategies for biological 
therapy
Strategies that can be employed when considering de-escalation of 
biological therapy in IBD are the following: 
• Discontinuation of biological therapy altogether is a possible 
strategy. The evidence for this has been discussed above. This 
must be considered when the patient is in deep clinical remission 
and biological drug levels are low. It is strongly recommended for 
the patient to be administered the highest possible dose of an IM 
that he/she can tolerate, which may be a very low dose. In the event 
of a previous adverse event or intolerance to an IM, it is prudent 
to maintain the patient on the lowest possible dose to avoid 
infusion reactions when restarting biological therapy. Should it 
be necessary to restart therapy, all available evidence suggests that 
the last used drug will be effective in >80% of patients. Therefore, 
one should restart with the biological agent last used. 
• Another form of de-escalation is to reduce the dose of the 
biological agent or to increase the dosing frequency. In the 
landmark TAXIT (Trough concentration Adapted infliXImab 
Treatment) study, patients in clinical remission with infliximab 
trough levels >7 μg/mL had dose de-escalation to a target trough 
level of 3 - 7 μg/mL. De-escalation was done by reducing the dose 
to 5 mg/kg (if previously 10 mg/kg) or by increasing the dose 
interval between infusions by 2 weeks (to a maximum of 12 weeks). 
Ninety-three percent of patients achieved the target range after 
dose reduction and remained in clinical remission. Fewer patients 
in the trough concentration dosing range discontinued treatment 
compared with those in the standard dosing group.[57] However, 
in the TAILORIX study, which investigated tailored treatment 
with infliximab for active CD, trough-level dosing in CD was not 
superior to symptom-based dosing in patients in remission.[58] After 
achieving remission with adalimumab standard 2-weekly dosing in 
CD, patients extended the dosing interval from 2 to 3 weeks, which 
resulted in sustained remission in 65% over 24 months, while in 
35% the dosing frequency was reduced to 2-weekly dosing.[59] 
These findings have been duplicated in a similar study that was 
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recently published.[60] In another study, CD and UC patients with 
refractory disease who previously required high-dose infliximab 
(10 mg/kg) and subsequently achieved remission, were scheduled 
to reduce the dose by 1 mg/kg at each infusion to reach a target of 
5 mg/kg infusion dose or a target trough level of 3 - 7 μg/mL. The 
majority of patients (n=18 - 20; 90%)[44] in this cohort remained 
well and in clinical remission, with adequate drug levels.[61] It 
seems, therefore, that a de-escalation strategy based on therapeutic 
drug monitoring can be effective, even in high-risk IBD patients 
with aggressive disease, who require dose escalation at some stage. 
Biological de-escalation: Who to target
The authors believe that all IBD patients should be considered for 
de-escalation of biological therapy at some point in their disease 
course. The proviso should be that these patients should be in deep 
clinical remission and exhibit the following:
• healed intestinal mucosa
• normal inflammatory markers – white cell count, erythrocyte 
sedimentation rate and CRP
• FC˂50 mg/mL
• low serum drug level.
However, there are certain patient groups in whom biological 
treatment de-escalation should be instituted with caution. As they 
are prone to frequent disease exacerbations, biological therapy 
withdrawal should be carefully planned and only embarked upon 
in those with mucosal healing. Frequent follow-up and clinical 
assessments are imperative, with prompt re-introduction of biologics 
at the first sign of disease recurrence. The following are included:
• young males
• patients with perianal CD
• patients with persistent mucosal ulceration
• patients with persistent elevation of inflammatory markers
• high-risk patients requiring frequent biological dose escalation or 
re-introduction
• patients who have undergone multiple surgical operations.
More data on this subject matter will be available in due course, as 
ongoing studies are currently being conducted (BIOCYCLE project 
and SPARE study) to evaluate the safety and efficacy to cycle biological 
agents in patients in deep clinical remission.[62] BIOCYCLE is a 6-year 
project that commenced in 2015. It aims to answer the question of 
biological drug withdrawal in patients with CD in an integrated, 
multidimensional and integrated fashion. SPARE is a prospective 
randomised controlled trial comparing infliximab-antimetabolites 
combination therapy to antimetabolites monotherapy and infliximab 
monotherapy in CD patients on combination therapy who are in 
sustained steroid-free remission. 
Conclusions
It is safe to de-escalate biological therapy in patients in deep clinical 
remission and in those receiving combination therapy. Evidence 
is not so robust in patients being administered a biological agent 
as monotherapy; more studies are needed in this regard. Before 
de-escalation of therapy, a frank discussion on the risks and benefits 
of the decision is mandatory. Although not ideal, de-escalation of 
biological treatment is often necessitated by cost, safety concerns 
and patient choice. However, the choice to de-escalate therapy 
should always be weighed against the risk of disease recurrence. As a 
general rule, patients who are in clinical, biochemical and endoscopic 
remission are more likely to remain in remission for longer. Although 
the majority of patients will eventually relapse, one should give 
patients a drug holiday. Some will never need re-introduction of 
therapy again.
The treatment of IBD has advanced tremendously over the years. 
Currently, there is personalised treatment for IBD. The high-risk 
patient has been identified and should be persuaded to continue 
receiving biological treatment for a longer period. It is incumbent 
upon clinicians to ensure that patients receive adequate doses 
with appropriate dosing intervals to guarantee mucosal healing. 
Therapeutic drug monitoring is a valuable tool in the modern 
management of IBD and should be judiciously employed, especially 
in patients who fail to respond appropriately. Merely escalating the 
dose of biological therapy in response to a low trough level in a 
patient who is otherwise doing clinically well is inappropriate. 
If concerned about stopping biological therapy outright, clinicians 
could consider either reducing the dose incrementally or increasing 
the dosing frequency. There is sufficient evidence for both strategies. 
It is reassuring to know that retreatment will be effective in most 
patients, and mostly with the same biological agent. Finally, also 
consider the psychological well-being of a patient with IBD off 
biological therapy, albeit only for a while.
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